<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN"
       "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.3" article-type="research-article" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="nlm-ta">Ulutas Med J</journal-id>
   <journal-title-group>
    <journal-title>The Ulutas Medical Journal</journal-title>
    <abbrev-journal-title>Ulutas Med J</abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="ppub">2149-0430</issn>
   <issn pub-type="epub">2149-388X</issn>
   <publisher>
    <publisher-name>Hayriye Zehra Ulutaş</publisher-name>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="doi">10.5455/umj.20150917042844</article-id>
   <article-id pub-id-type="publisher-id">201089</article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>Original Research</subject>
    </subj-group>
    <subj-group subj-group-type="subject">
     <subject>Child Psychiatry</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title>Antibiotic Susceptibilities of Enterococci Isolated from Blood Cultures</article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5372-1237</contrib-id>
     <name name-style="western">
      <surname>Durmaz</surname>
      <given-names>Süleyman</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff1">1</xref>
    </contrib>
    <contrib contrib-type="author">
     <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6125-2031</contrib-id>
     <name name-style="western">
      <surname>Özer</surname>
      <given-names>Türkan Toka</given-names>
     </name>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
     <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
     <xref ref-type="aff" rid="aff2">2</xref>
    </contrib>
    <aff id="aff1">
     <label>1</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/00acd3d73</institution-id>
      <institution>Konya Numune Hospital, Microbiology Laboratory, Konya, Turkey</institution>
     </institution-wrap>
    </aff>
    <aff id="aff2">
     <label>2</label>
     <institution-wrap>
      <institution-id institution-id-type="ror">https://ror.org/00zv6rh96</institution-id>
      <institution>Mevlana University Faculty of Medicine, Department of Medical Microbiology, Konya, Turkey</institution>
     </institution-wrap>
    </aff>
   </contrib-group>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2015-12-28">
    <day>28</day>
    <month>12</month>
    <year>2015</year>
   </pub-date>
   <pub-date publication-format="print" date-type="collection">
    <year>2015</year>
   </pub-date>
   <volume>1</volume>
   <issue>4</issue>
   <fpage>111</fpage>
   <lpage>115</lpage>
   <history>
    <date date-type="received" iso-8601-date="2015-09-10">
     <day>10</day>
     <month>09</month>
     <year>2015</year>
    </date>
    <date date-type="rev-recd" iso-8601-date="2015-10-03">
     <day>03</day>
     <month>10</month>
     <year>2015</year>
    </date>
    <date date-type="accepted" iso-8601-date="2015-10-17">
     <day>17</day>
     <month>10</month>
     <year>2015</year>
    </date>
   </history>
   <permissions>
    <copyright-statement>© 2015 The Author(s)</copyright-statement>
    <copyright-year>2015</copyright-year>
    <license>
     <ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
     <license-p>This is an open access article distributed under the CC BY-NC 4.0 licence.</license-p>
    </license>
   </permissions>
   <self-uri xlink:href="https://www.ulutasmedicaljournal.com/?mno=201089"/>
   <self-uri content-type="pdf" xlink:href="https://www.ulutasmedicaljournal.com/pdf/201089.pdf"/>
   <abstract>
    <p>Objective: The aim of this study was to determine the enterococci species and antimicrobial resistance rates of enteroccus strains isolated from blood cultures of inpatients. Materials and Methods: One hundred five Enterococcus spp. strains isolated from blood cultures sent from clinics at Osmaniye State Hospital Microbiology Laboratory between January 2011-December 2013 were included. The isolates were identified by conventional methods and Vitek 2 automated system. Antibiotic susceptibility tests were performed by disk-diffusion method and E-test. Statistical analysis was performed using chi-square test. Results: Enterococcus spp. strains evaluated, 54(51.4%) were identified as E.faecalis and 51(48.6%) as E.faecium. General Intensive Care Unit(GICU) is the section where most frequently isolated species of both enterococci. Other clinics were Dialysis unit, and Internal Medicine clinics. E.faecium strains were found to be resistant to ampicillin, erythromycin, ciprofloxacin. Resistance rates of E.faecalis strains against ampicillin, erythromycin, ciprofloxacin were 47%, 70.5%, 11.8%, respectively. High-level resistance to gentamicin and streptomycin were determined in 55.6%, 83.3% of E.faecium strains and in 23.5%, 11.8% of E.faecalis strains, respectively (p≤0.05). Two of E.faecium strains and 1 of E.faecalis from GICU were found to be resistant to teicoplanin and vancomycin. Linezolid was found most effective drug and resistance wasn't determined in none of the strains. Conclusions: Three vancomycin and teicoplanin resistant strains isolated from blood cultures in our hospital show that the isolates mentioned above may cause significant problems in the future. In addition, linezolid may be a good alternative for the treatment of the resistant enterococcal infections in our hospital.</p>
   </abstract>
   <kwd-group kwd-group-type="author">
    <kwd>Blood culture</kwd>
    <kwd>Enterococcus facium</kwd>
    <kwd>Enterococcus faecalis</kwd>
    <kwd>antibiotic susceptibility</kwd>
    <kwd>E-test</kwd>
    <kwd>disk diffusion</kwd>
   </kwd-group>
   <funding-group>
    <funding-statement>Funding information was not reported in the published version of this article.</funding-statement>
   </funding-group>
  </article-meta>
 </front>
 <body>
  <sec id="sec-1">
   <title>Introduction</title>
   <p id="b-1">Enterococci become one of the most common nosocomial infection agents that have high mortality rate in recent years. Cause of this situation could be considered as resistance of enterococci to difficult environmental conditions, cephalosporins, lincosamides, trimethoprim-sulfamethoxazole (TMP-SXT), inherent low level of resistance to aminoglycosides (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref2">2</xref>
). However, all these properties found always in enterococci, this increase has not fully explained in recent years. The results of the studies showed that real reason for this increase was enterococcal colonization selectively and to become the dominant flora in the gastrointestinal tract as a result of frequent use of antibiotics as 3rd generation cephalosporins, metronidazole, carbapenem, clindamycin that were noneffective or restricted effect on enterococci in the hospitals (    <xref ref-type="bibr" rid="ref3">3</xref>
). Enterococci in hospitals can cause infections such as such as urinary tract infections, skin and soft tissue infections, bacteremia, peritonitis, meningitis especially resulting from gastrointestinal flora in immunocomprimized patients (    <xref ref-type="bibr" rid="ref4">4</xref>
). It was indicated that enterococci were second most common cause of skin and soft tissue infections and third most common cause of bacteremia in the studies (    <xref ref-type="bibr" rid="ref5">5</xref>
).</p>
   <p id="b-2">Increase in the resistance rate of Enterococci to antibiotics and high mortality rate in bacteremia compared to other clinical situations were shown by the studies (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref6">6</xref>
). Initiation of appropriate empiric treatment in the bacteremic patients was stated that change prognosis in the right direction (    <xref ref-type="bibr" rid="ref7">7</xref>
,    <xref ref-type="bibr" rid="ref8">8</xref>
). In bacteremia caused by enterococci, determination of antibiotic susceptibility for the initiation of the appropriate empirical treatment, follow-up and analysis of the data is very important.</p>
   <p id="b-3">This study was performed to determine     <italic>enterococcus spp.</italic>
 strains patterns of antimicrobial resistance including glycopeptides and linezolid.</p>
  </sec>
  <sec id="sec-2">
   <title>Study Design</title>
   <p id="b-4">One hundred five Enterococcus strains isolated from blood cultures sent from clinics at Osmaniye State Hospital Microbiology Laboratory between January 2011-December 2013 were included in this study. The study protocol was reviewed and approved by the secretary general of the Osmaniye association of public hospitals ethics committee. Blood culture were studied with BACTEC 9240 (Becton Dickinson, Sparks, Md., USA) automated blood culture system. The isolates were identified by conventional methods and VITEK-2 system (BioMerieux, France). Antibiotic susceptibility tests were performed by the Kirby-Bauer disk-diffusion method according to the standards of Clinical and Laboratory Standards Institute (    <xref ref-type="bibr" rid="ref9">9</xref>
).</p>
   <p id="b-5">Intermediate susceptible strains were considered as resistant. For high-level resistance to aminoglycoside, gentamicin 120 mcg and 300 mcg of streptomycin discs were used. High-level resistance to aminoglycoside was also studied by the agar screening test. Minimum inhibitory concentrations (MIC) were determined by E-test (AB Biodisk, Sweden) for all isolates showing decreased susceptibility to vancomycin and teicoplanin by disk diffusion method. The test was quality controlled by using     <italic>E. fecalis</italic>
 ATCC 29212. Statistical Analysis was performed using SPSS software. The chi-square test was used to test the statistical differences.</p>
  </sec>
  <sec id="sec-3">
   <title>Results</title>
   <p id="b-6">Enterococcus strains evaluated, and among of 105, 54 (51.4%) were identified as     <italic>E. faecalis</italic>
 and 51 (48.6%) as     <italic>E. faecium. </italic>
General Intensive Care Unit (GICU) is the section where the most frequently isolated species of both enterococci. Other clinics were Dialysis unit and Internal Medicine clinics (    <italic>Table-1</italic>
).</p>
   <table-wrap id="tbl-1" position="float">
    <label>Table 1</label>
    <caption>
     <title>Distribution of clinics and species of enterococci isolated from blood cultures</title>
    </caption>
    <graphic xlink:href="tbl-1.png">
     <alt-text>Table 1: Distribution of clinics and species of enterococci isolated from blood cultures</alt-text>
    </graphic>
   </table-wrap>
   <p id="b-7">All of     <italic>E. faecium</italic>
 strains were found to be resistant to ampicillin, erythromycin, ciprofloxacin. Resistance rates of     <italic>E. faecalis</italic>
 against ampicillin, erythromycin, ciprofloxacin were as 47%, 70.5%, 11.8%, respectively. High level resistance to gentamicin and streptomycin were determined in 55.6%, 83.3% of     <italic>E. faecium</italic>
 strains strains (p≤0.05).</p>
   <p id="b-8">and in 23.5%, 11.8% of     <italic>E. faecalis </italic>
Resistance rate of both strains against tetracyclin was similiar, but found to be higher in E.faecalis strains. Both 2 of E. faecium strains and 1 of E. faecalis from GICU were found to be resistant to teicoplanin and vancomycin. MIC values of all the strains for vancomycin was determined as ≥256 µg/mL, for teicoplanin was determined as ≥64 µg/mL. Linezolid was found most effective drug and resistance wasn’t determined in none of the strains (    <italic>Table-2</italic>
).</p>
   <table-wrap id="tbl-2" position="float">
    <label>Table 2</label>
    <caption>
     <title>Susceptibility of E.faecalis and E.faecium to 9 antibiotics</title>
    </caption>
    <graphic xlink:href="tbl-2.png">
     <alt-text>Table 2: Susceptibility of E.faecalis and E.faecium to 9 antibiotics</alt-text>
    </graphic>
   </table-wrap>
  </sec>
  <sec id="sec-4">
   <title>Discussion</title>
   <p id="b-9">Gram-negative bacteria were frequently isolated in the 1970s, while after the 1990s gram-positive bacteria has come to the forefront in bacteremia. Enterococci found in normal flora are isolated from bacteremia at an increasing rate. In studies from England in 2005, enterococci in bacteremic agents were isolated more than 8% compared to the previous year (    <xref ref-type="bibr" rid="ref3">3</xref>
,    <xref ref-type="bibr" rid="ref10">10</xref>
). Besides, being naturally resistance of enterococci to many antibiotics, gaining new resistance mechanisms and transferring it to the new generation can be an indication of a more important issue in the future. Enterococci are naturally resistant to aminoglycosides (except for high level of aminoglycosides), cephalosporins, clindamycin and trimethoprim/sulfamethoxazole. Beta-lactams has limited clinical efficacy on enterococci due to the low affinity PBPs. In addition, enterococci may acquire resistance to high levels aminoglycosides, macrolides, streptogramin, tetracycline, rifampin, chloramphenicol, fluoroquinolones and glycopeptides (    <xref ref-type="bibr" rid="ref10">10</xref>
).</p>
   <p id="b-10">Usually, enterococci that cause infections in patients with impaired host defense lead to difficulty in the treatment due to their ability to acquire resistance to very large groups of antibiotics. Although enterococci are the members of the gastrointestinal system flora,     <italic>E. faecalis </italic>
are dominant than     <italic>E. faecium</italic>
. Therefore,     <italic>E. faecalis </italic>
isolated more frequently as an infectious agent in clinical samples. However, it is stated that isolation of     <italic>E. faecium </italic>
is seen especially from the blood in enterococcal infection in the recent years studies (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref11">11</xref>
).</p>
   <p id="b-11">Recent studies were reported that 42-67% of enterococ isolated from bacteremia was     <italic>E. Faecium </italic>
in our country (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref2">2</xref>
,    <xref ref-type="bibr" rid="ref11">11</xref>
). In the study, E.faecium rate is 51.4% that supports     <italic>E. faecium</italic>
 more frequently isolated in bacteremia.</p>
   <p id="b-12">It was reported antibiotic resistance with increasing rates in enterococcus species and these rates varies among species. Ampicillin that antibiotics can be preferred in enterococcal infection resistance have been reported in 39-93% and 4-52% as for     <italic>E. faecium </italic>
isolates and     <italic>E.faecalis</italic>
 studies in studies from Turkey, respectively (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref2">2</xref>
,    <xref ref-type="bibr" rid="ref11">11</xref>
). In this study, ampicillin resistance were determined in     <italic>E. faecium</italic>
 isolates as 100%, for     <italic>E.faecalis</italic>
 isolates as 47%. Rate of ampicillin resistance in     <italic>E.faecium</italic>
 isolates were found higher than     <italic>E.faecalis </italic>
isolates that was statistically significant.</p>
   <p id="b-13">Erythromycin was another most preferred antibiotic in enterococcal infection. Due to resistance to erythromycin that was one of the macrolide has similar resistance mechanism with clindamycin and streptogramin B, resistance in one of these antibiotics appear as resistance to other antibiotics (    <xref ref-type="bibr" rid="ref12">12</xref>
). Studies have shown that erythromycin resistance was found higher in E. faecium isolates than in     <italic>E. faecalis</italic>
 isolates. Berktas et al(    <xref ref-type="bibr" rid="ref1">1</xref>
), detected erythromycin resistance in the isolates of     <italic>E. faecalis </italic>
and    <italic> E. faecium</italic>
 as 47% and 88%, Gozubuyuk et al(    <xref ref-type="bibr" rid="ref11">11</xref>
) 56.3% and 80.3%, Turkdağı et al(    <xref ref-type="bibr" rid="ref2">2</xref>
) detected in 79% and 99%. In this study, resistance rate was detected 70.5% in     <italic>E. faecalis</italic>
 isolates, 100% in     <italic>E. faecium</italic>
 isolates. Our results were found to be compatible with literature. Tetracycline resistance occurs with different genes as tetL, tet M, tetN ve tetO in enterococci and with spreading of these genes by conjugation (    <xref ref-type="bibr" rid="ref13">13</xref>
). Tetracycline resistance rate in enterococci strains isolated from various clinical specimens in Turkey was found between 28-52% (    <xref ref-type="bibr" rid="ref14">14</xref>
,    <xref ref-type="bibr" rid="ref15">15</xref>
). Gozubuyuk et al detected tetracycline resistance as 62.5% in the     <italic>E. faecalis</italic>
 strains isolated from blood cultures, and 22.9% of     <italic>E. faecium</italic>
 strains (    <xref ref-type="bibr" rid="ref11">11</xref>
). Tetracycline resistance in our study, was 88.2% for     <italic>E. faecalis</italic>
, and 82.3% for     <italic>E. faecium</italic>
. These results showed that high tetracycline resistance for both types of enterococcus and should be avoided from use of tetracycline for empirical treatment. Quinolones in combination therapy with other antibiotics for the treatment of enterococcus often preferred (    <xref ref-type="bibr" rid="ref8">8</xref>
,    <xref ref-type="bibr" rid="ref12">12</xref>
). Meric et al(    <xref ref-type="bibr" rid="ref16">16</xref>
) found ciprofloxacin resistance rates for     <italic>E. faecalis</italic>
 strains as 21% and as 78% for E    <italic>. faecium</italic>
 strains, Berktas et al(    <xref ref-type="bibr" rid="ref1">1</xref>
) found that 21% and 60%, Turkdagı et al (    <xref ref-type="bibr" rid="ref2">2</xref>
) found that 61% and 85% respectively. In this study, 11.8% in     <italic>E.faecalis </italic>
strains and 100% in     <italic>E.faecium</italic>
 strains. Resistance rate of ciprofloxacin in     <italic>E. faecium</italic>
 strains were found statistically significantly higher than     <italic>E. faecalis</italic>
. Too high ciprofloxacin resistance in     <italic>E. faecium</italic>
 strains was considered worrisome on behalf of hospital. Quinolones was thought to be appropriate in the treatment of enterococci infections with determining quinolone antibiotic susceptibility and identification of the species.</p>
   <p id="b-14">Enterococci are naturally resistant to low-level aminoglycoside but high levels of aminoglycosides (HLA) can be used in treatment.12 HLA resistance in Turkey according to data of multicenter study were found to be 48.1% and this rate was reported to be the second highest value in the European countries.17 Gales et al.18 found high level gentamycin resistance (gentamycin) as 29% in     <italic>E. faecalis</italic>
 strains, 11% in     <italic>E. faecium</italic>
 strains, a high level streptomycin resistance (streptomisinh) as 25%, 77% respectively. Meric et al(    <xref ref-type="bibr" rid="ref16">16</xref>
) reported that resistance rate of gentamycinh as 13% and 41%, streptomisinh as 22%, 67% in     <italic>E.faecalis</italic>
 and     <italic>E.faecium</italic>
 strains respectively. In another study, gentamisinh resistance of     <italic>E. faecalis </italic>
and    <italic> E. faecium</italic>
 strains were detected as 14% and 52%, streptomisinh resistance were found to be 11%, 62%, respectively (    <xref ref-type="bibr" rid="ref19">19</xref>
). Gentamisinh resistance in our study was 23.5% and 55.6%, streptomisinh resistance was 11.8% and 83.3% in     <italic>E.faecalis </italic>
and    <italic> E.faecium</italic>
 strains respectively. According to the results of our study, HLA in     <italic>E. faecium </italic>
strains were detected significantly higher than     <italic>E.faecalis </italic>
strains and also HLA observed higher than from the other studies in the literature.</p>
   <p id="b-15">Glycopeptides have been effectively used for a long time due to emergence and gradually increase of enterococci resistance to the beta-lactam antibiotics and amino glycosides. For first time in 1987, reporting vancomycin resistant enterococci (VRE) have been reported in France and in the UK, this should be thought that VRE would be cause serious problems in the future (    <xref ref-type="bibr" rid="ref9">9</xref>
). In our country, the first VRE were reported in 1998 (    <xref ref-type="bibr" rid="ref20">20</xref>
). In multicenter study SENTRY conducted in 2005, VRE rate was 0% in France, Sweden and Switzerland, 66.7 % in the UK, 71.4% in Ireland. In this study, the resistance rate of     <italic>E.faecalis</italic>
 was 0%, while in     <italic>E.faecium</italic>
 was 8.6% in Turkey (    <xref ref-type="bibr" rid="ref1">1</xref>
). In studies from Turkey in recent years, vancomycin and teicoplanin resistance rate in     <italic>E. faecium </italic>
strains as 0-24 %, while the rate of resistance in     <italic>E. faecalis </italic>
strains have been reported in 0-5% (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref2">2</xref>
,    <xref ref-type="bibr" rid="ref11">11</xref>
). In our study of vancomycin and teicoplanin resistance has been seen in the same strains and detected in two (3.7%) E. faecium and one (1.9%) in     <italic>E. faecalis</italic>
 strains. All of the strains isolated from GICU and     <italic>E. faecium</italic>
 strains isolated at the same time. This result was thought that transmission of infection between the patients. In this case, more attention should be paid to our hospital infection control measures, the implementation of rapid and accurate diagnostic methods to prevent possible outbreaks and surveillance studies.</p>
   <p id="b-16">Linezolid is effective against gram-positive bacteria, including VRE, MRSA, multidrug resistant staphylococci, penicillin-resistant Streptococcus pneumoniae (    <xref ref-type="bibr" rid="ref21">21</xref>
,    <xref ref-type="bibr" rid="ref22">22</xref>
). Multicenter study conducted in United States, vancomycin resistance was detected in 10% of     <italic>E. faecalis</italic>
, only a strain was found intermediate susceptible to linezolid. The vancomycin resistance was detected in 76.9%, linezolid resistance was found to be 1.5% in     <italic>E. faecium</italic>
 strains in the same study (    <xref ref-type="bibr" rid="ref23">23</xref>
). Linezolid resistance has been reported in studies from Turkey between 0-4 % in both species (    <xref ref-type="bibr" rid="ref1">1</xref>
,    <xref ref-type="bibr" rid="ref2">2</xref>
,    <xref ref-type="bibr" rid="ref11">11</xref>
). In our study, linezolid resistance was not observed in any strain. Monitoring antibiotic susceptibility pattern of each center has an important role in the infection control for early diagnosis and initiation of appropriate empirical treatment in bacteremia that has high mortality rate and caused by enterococci.</p>
   <p id="b-17">Made of     <italic>E. faecalis-E</italic>
.    <italic>faecium</italic>
 species distinction will be an important guiding empiric therapy due to statistically significant differences between species in the resistance rate to antibiotics, as in our study.</p>
  </sec>
  <sec id="sec-5">
   <title>Conclusion</title>
   <p id="b-18">Vancomycin was still found to be an effective agent against both enterococci species, although more frequently encountered every day with VRE infections. Isolation of three VRE strains from blood cultures in our hospital shows that infections related to enterocci could lead to bigger problems in the future. In this study, it was determined that linezolid was found to be effective against all strains including VRE strains and to be a good alternative in enterococcal infections. It was considered that to follow susceptibility patterns of linezolid which was one of the rare option in the treatment of VRE infections and to limit unnecessary clinical use would be more appropiate.</p>
  </sec>
 </body>
 <back>
  <ref-list>
   <title>References</title>
   <ref id="ref1">
    <label>1</label>
    <mixed-citation publication-type="journal">Berktas M, Cıkman A, Parlak M, Guducuoğlu H, Ozkacmaz A. The Antibiotic resistance of Enterococcus strains isolated from blood cultures. Sakaryamj 2013;3:76-79.</mixed-citation>
   </ref>
   <ref id="ref2">
    <label>2</label>
    <mixed-citation publication-type="journal">Turk Dagı H, Arslan U, Tuncer EI. Antibiotic resistance in Enterococci isolated from blood cultures. Turkish Society Microb 2011;41:103-106.</mixed-citation>
   </ref>
   <ref id="ref3">
    <label>3</label>
    <mixed-citation publication-type="journal">Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009; 155: 1749-1757.</mixed-citation>
   </ref>
   <ref id="ref4">
    <label>4</label>
    <mixed-citation publication-type="journal">Sava IG, Heikens E, Huebner J. Pathogenesis and immunity in enterococcal infections. Clin Microbiol Infect 2010;16:533-540.</mixed-citation>
   </ref>
   <ref id="ref5">
    <label>5</label>
    <mixed-citation publication-type="journal">De Fatima Silva Lopes M, Ribeiro T, Abrantes M, Figueiredo Marques JJ, Tenreiro R, Crespo MT. Antimicrobial resistance profiles of dairy and clinical isolates and type strains of enterococci. Int J Food Microbiol 2005;103:191-198.</mixed-citation>
   </ref>
   <ref id="ref6">
    <label>6</label>
    <mixed-citation publication-type="journal">Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. American journal of medicine 2006;119:970-976.</mixed-citation>
   </ref>
   <ref id="ref7">
    <label>7</label>
    <mixed-citation publication-type="journal">Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest Journal 2000;118:146-155.</mixed-citation>
   </ref>
   <ref id="ref8">
    <label>8</label>
    <mixed-citation publication-type="journal">Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective Ulutas Med J 2015;1(4):111-115 Süleyman Durmaz et al. Antibiotic Susceptibilities of Enterococcus antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine 2006;34:1589-1596</mixed-citation>
   </ref>
   <ref id="ref9">
    <label>9</label>
    <mixed-citation publication-type="journal">Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement M100-S18, CLSI, Wayne, Pa (2008).</mixed-citation>
   </ref>
   <ref id="ref10">
    <label>10</label>
    <mixed-citation publication-type="journal">Tunger O. The old and new treatment options for vancomycin-resistant enterococcal infections. Ankem Journal 2012;26:215-227.</mixed-citation>
   </ref>
   <ref id="ref11">
    <label>11</label>
    <mixed-citation publication-type="journal">Gozuboyuk G, Uyanik MH, Hancı H, Aktas O, Ozbek A. Antimicrobial susceptibility of Enterococcus strains isolated from blood cultures. Ankem Journal 2013;27:107-112.</mixed-citation>
   </ref>
   <ref id="ref12">
    <label>12</label>
    <mixed-citation publication-type="journal">Durmaz S, Kiraz A, Ozer TT, Percin D. Macrolide-lincosamide-streptogramin B resistance phenotypes in Staphylococcus aureus. Eur J Gen Med 2014;11:217-220.</mixed-citation>
   </ref>
   <ref id="ref13">
    <label>13</label>
    <mixed-citation publication-type="journal">Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65.</mixed-citation>
   </ref>
   <ref id="ref14">
    <label>14</label>
    <mixed-citation publication-type="journal">Eksi F, Gayyurhan ED. Antibiotic susceptibility of Streptococcus and Enterococcus strains isolated from clinical specimens. Ankem Journal 2008;22:53-58.</mixed-citation>
   </ref>
   <ref id="ref15">
    <label>15</label>
    <mixed-citation publication-type="journal">Kalayci O, Yurtsever SG, Gungor S, Uzun B, Kurultay N. Evaluation of in vitro antibiotic sensitivity of Enterococci isolated from urine samples. Klimik Journal 2011;24:105-107.</mixed-citation>
   </ref>
   <ref id="ref16">
    <label>16</label>
    <mixed-citation publication-type="journal">Meric M, Ruzgar M, Gundes S, Willke A. Enterococcus species isolated from hospitalized patients and their antibiotic resistance patterns. Ankem Journal 2004;18:141-144.</mixed-citation>
   </ref>
   <ref id="ref17">
    <label>17</label>
    <mixed-citation publication-type="journal">Sumerkan B. Antibiotic resistance in Streptococcus pneumoniae and Enterococci: Map of Turkey (2003-2004). Ankem Journal 2005;19:61-65.</mixed-citation>
   </ref>
   <ref id="ref18">
    <label>18</label>
    <mixed-citation publication-type="journal">Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in SENTRY Program (2005-2008). Br az J Infect Dis 2009;13:90-98.</mixed-citation>
   </ref>
   <ref id="ref19">
    <label>19</label>
    <mixed-citation publication-type="journal">Mert Dinc B, Aykut Arca E, Yağcı S, Karabiber N. In-vitro antibotic susceptibility of Enterococcus faecalis and Enterococcus faecium strains isolated from various clinical samples. Turk Hij Den Biyol Derg. 2009;66: 117-121.</mixed-citation>
   </ref>
   <ref id="ref20">
    <label>20</label>
    <mixed-citation publication-type="journal">Vural T, Sekercioglu AO, Ogunc D, Gultekin M, Colak D, Yesilipek A, et al. Vancomycin resistant Enterococcus faecium strain. ANKEM Journal 1999;13:1-4</mixed-citation>
   </ref>
   <ref id="ref21">
    <label>21</label>
    <mixed-citation publication-type="journal">Barrett JF. Linezolid Pharmacia Corp. Curr Opin Invest Drugs 2000;1:181-187.</mixed-citation>
   </ref>
   <ref id="ref22">
    <label>22</label>
    <mixed-citation publication-type="journal">Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975-1982</mixed-citation>
   </ref>
   <ref id="ref23">
    <label>23</label>
    <mixed-citation publication-type="journal">Jones RN, Ballow CH, Biedenbach DJ and ZAPS Study Group Medical Centers. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the “Zyvox Antimicrobial Potency Study” (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001; 40:59-66.</mixed-citation>
   </ref>
  </ref-list>
 </back>
</article>
